From MIC Data to Actionable Surveillance Reports

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Build an AMR surveillance report from MIC data by organizing isolates into pathogen-antimicrobial combinations, calculating susceptibility percentages, and presenting MIC distributions alongside categorical interpretations.
• Use the template structure below to standardize data cleaning, analysis, and stakeholder communication, with WHONET or equivalent software for data management.
• A critical limitation is that MIC data only reflect in vitro activity and require clinical breakpoints from standards organizations to translate into categorical results.

At a Glance

Purpose of an AMR Surveillance Report

Antimicrobial resistance surveillance transforms raw laboratory data into information that supports treatment decisions, infection control actions, and antimicrobial stewardship programs. The clinical microbiology laboratory plays a critical role in this process by providing guidance for antimicrobial treatment, yet the value of susceptibility testing depends on how results are aggregated, interpreted, and communicated to stakeholders [<a href="#ref-1">1</a>]. A surveillance report is the bridge between individual patient results and population-level action.

The World Health Organization defines antimicrobial resistance as a global health threat that requires coordinated surveillance across human health, animal health, and environmental sectors [<a href="#ref-2">2</a>]. For a laboratory manager or public health analyst, the surveillance report serves multiple audiences with different needs. Clinicians need to know which antimicrobials remain effective for empirical therapy. Infection prevention teams need to identify resistant organism clusters that may indicate transmission. Stewardship committees need trend data to evaluate whether prescribing interventions are working. Administrators need concise summaries to justify resource allocation.

A standardized template ensures that each report answers the same questions consistently. Without standardization, comparisons across time periods or between facilities become unreliable. The template presented here follows the logic used in published surveillance studies, which typically analyze bacterial isolates from defined patient populations, calculate resistance rates for key pathogen-antimicrobial combinations, and examine trends over time [<a href="#ref-3">3</a>].

Core Principles of MIC Data Interpretation

Minimum Inhibitory Concentration as the Foundation

The minimum inhibitory concentration is the lowest concentration of an antimicrobial that prevents visible growth of a microorganism under standardized testing conditions. MIC values are quantitative measurements expressed in micrograms per milliliter (µg/mL). They provide more information than a simple susceptible, intermediate, or resistant category because they show how close an isolate is to the breakpoint threshold.

MIC data are generated through established antimicrobial susceptibility testing methods. The Clinical and Laboratory Standards Institute publishes standards for susceptibility testing that define testing conditions, quality control requirements, and interpretive criteria [<a href="#ref-4">4</a>]. These standards ensure that MIC values from different laboratories or different time periods can be meaningfully compared. Laboratories that do not follow standardized methods produce data that cannot be reliably aggregated into surveillance reports.

From MIC to Categorical Interpretation

Clinical breakpoints translate continuous MIC values into categorical results. A susceptible result indicates that the organism is likely to respond to treatment with the standard dosing regimen. An intermediate result suggests that the organism may respond at higher doses or in body sites where the antimicrobial concentrates. A resistant result indicates that the organism is unlikely to respond to treatment.

Breakpoints are established by standards organizations based on pharmacokinetic and pharmacodynamic data, clinical outcome studies, and microbiological considerations. The specific breakpoint values are published in standards documents and are periodically revised as new evidence emerges [<a href="#ref-4">4</a>]. A surveillance report must document which breakpoint version was used because changing breakpoints can alter resistance percentages even when the underlying MIC data are unchanged.

The Role of Quality Control in Data Reliability

Quality control organisms with known MIC ranges are tested alongside clinical isolates to verify that testing conditions are performing correctly. If QC results fall outside the expected range, the clinical results from that batch may be unreliable and should not be included in surveillance analyses. The American Type Culture Collection maintains authenticated reference strains that serve as standardized QC organisms [<a href="#ref-5">5</a>].

A surveillance report should include a summary of QC performance for the reporting period. This documentation allows stakeholders to assess data confidence. Laboratories that consistently pass QC can produce surveillance data with greater reliability than those with frequent QC failures.

Building the Surveillance Dataset

Defining the Study Population

The first step in creating a surveillance report is defining which isolates will be included. Published surveillance studies typically specify inclusion criteria such as patient location, specimen type, time period, and whether duplicate isolates from the same patient are excluded. For example, a dermatology surveillance study analyzed bacterial isolates from dermatology patients between 2018 and 2023, with specific attention to specimen types and patient demographics [<a href="#ref-3">3</a>].

Common inclusion decisions include whether to include only clinically significant isolates or all isolates from a specimen type, whether to include only the first isolate per patient per time period or all isolates, and whether to restrict analysis to specific specimen sources such as blood, urine, or respiratory samples. Each decision affects the interpretation of the results. Including all isolates overcounts patients with multiple positive cultures. Restricting to first isolates provides a patient-level perspective but may miss within-patient resistance development.

Data Fields Required for Each Isolate

Each isolate record in the surveillance dataset should include the following fields:

The organism identification must be accurate because resistance patterns differ substantially between species. Coagulase-negative staphylococci, for example, exhibit higher antimicrobial resistance than Staphylococcus aureus in some patient populations [<a href="#ref-3">3</a>]. Misidentification would distort the resistance percentages for both species groups.

Handling Duplicate Isolates

Duplicate isolates from the same patient can bias surveillance results. A patient with a prolonged infection who is cultured multiple times will contribute multiple isolates to the dataset. If that patient carries a resistant organism, the resistance percentage will be inflated by repeated sampling.

The standard approach is to include only the first isolate per patient per defined time period, typically 30 days, for each organism species. This approach is called the first isolate per patient rule. The surveillance report should document the deduplication method so that stakeholders understand how the denominator was constructed.

Data Cleaning and Validation

Before analysis, the dataset must be checked for errors. Common problems include MIC values that fall outside the tested range, categorical results that do not match the MIC value, missing organism identifications, and duplicate records. Automated validation rules can flag these issues, but manual review is often needed for ambiguous cases.

The World Health Organization promotes standardized surveillance approaches that include data quality checks [<a href="#ref-2">2</a>]. Laboratories should establish data cleaning protocols that document every modification made to the raw data. This audit trail supports data integrity and allows the analysis to be reproduced.

Analyzing MIC Distributions

Constructing MIC Distribution Tables

An MIC distribution table shows the number or percentage of isolates inhibited at each tested concentration for a specific pathogen-antimicrobial combination. The table typically lists concentrations in doubling dilutions across the columns and the number of isolates at each concentration in the rows.

MIC distributions reveal patterns that categorical results obscure. A bimodal distribution with peaks at very low and very high concentrations suggests a population with two distinct susceptibility groups, which may indicate the presence of a resistance mechanism in the high-MIC group. A unimodal distribution with a gradual shift toward higher MICs over time may indicate emerging low-level resistance that has not yet crossed the clinical breakpoint.

The Clinical and Laboratory Standards Institute recommends that laboratories track MIC distributions as part of their quality assurance activities [<a href="#ref-4">4</a>]. Shifts in the modal MIC for a QC organism or for clinical isolates can signal testing drift before categorical results change.

Presenting MIC50 and MIC90 Values

The MIC50 and MIC90 are the MIC values that inhibit 50% and 90% of the tested isolates, respectively. These summary statistics provide a compact description of the MIC distribution. The MIC50 represents the typical susceptibility of the population, while the MIC90 describes the more resistant end of the distribution.

These values are calculated by ranking all MIC values for a pathogen-antimicrobial combination and identifying the value at the 50th and 90th percentiles. When the MIC90 is much higher than the MIC50, the population contains a substantial subpopulation with reduced susceptibility. When both values are close to the clinical breakpoint, the organism population is approaching resistance even if the categorical resistance percentage remains low.

Visualizing MIC Distributions

A histogram or bar chart showing the percentage of isolates at each MIC concentration is the most informative visualization for MIC distribution data. The chart should include the clinical breakpoint as a reference line so that readers can see how the distribution relates to the categorical interpretation.

For temporal comparisons, MIC distributions from different time periods can be overlaid on the same chart. This visualization makes shifts in the distribution immediately apparent. A distribution that moves to the right over time indicates decreasing susceptibility even before categorical resistance percentages increase.

Calculating Resistance Percentages

Defining Numerators and Denominators

The resistance percentage for a pathogen-antimicrobial combination is calculated by dividing the number of resistant isolates by the total number of isolates tested for that combination. The denominator should include all isolates with a categorical result for that antimicrobial, including those classified as susceptible, intermediate, or resistant.

Some surveillance reports calculate the percentage of susceptible isolates instead of the percentage of resistant isolates. The choice depends on the audience and the purpose of the report. Susceptibility percentages are often preferred for clinical guidance because they directly indicate the likelihood that empirical therapy will be effective. Resistance percentages are often preferred for stewardship and infection control because they highlight the problem organisms.

Handling Intermediate Results

Intermediate results create a classification challenge. Some surveillance reports combine intermediate and resistant results into a single nonsusceptible category. Other reports treat intermediate results as a separate category and calculate resistance percentages using only resistant isolates in the numerator.

The approach should be documented in the report methodology. Combining intermediate with resistant results provides a conservative estimate of antimicrobial effectiveness. Treating intermediate separately provides more granular information but requires larger sample sizes to produce stable percentages.

Confidence Intervals for Resistance Percentages

Resistance percentages based on small numbers of isolates are unstable. A percentage based on 5 isolates can change dramatically with the addition of a single isolate. Confidence intervals quantify this uncertainty and should be included in surveillance reports.

For a resistance percentage based on a small denominator, the confidence interval will be wide, indicating low precision. Stakeholders should interpret resistance percentages with wide confidence intervals cautiously. The report should flag combinations with fewer than a minimum number of isolates, typically 10 or 30 depending on the context, as having limited reliability.

Analyzing Temporal Trends

Selecting the Time Unit for Trend Analysis

Temporal trends can be analyzed by year, quarter, or month. The choice of time unit depends on the volume of isolates and the purpose of the analysis. Annual analysis provides stable estimates but may miss rapid changes. Monthly analysis detects changes quickly but produces noisy estimates when isolate numbers are low.

Published surveillance studies often analyze trends across multiple years. The dermatology surveillance study examined changes from 2018 to 2023 and used statistical tests to identify significant trends [<a href="#ref-3">3</a>]. A similar approach can be applied at the facility level with appropriate attention to isolate volumes.

Statistical Tests for Trend Detection

The Cochran-Armitage test for trend is commonly used to assess whether resistance percentages change significantly across ordered time periods. This test evaluates whether there is a monotonic increase or decrease in the proportion of resistant isolates over time. Chi-square tests can compare resistance percentages between two time periods or between different patient groups [<a href="#ref-3">3</a>].

Statistical significance should not be the only criterion for action. A trend that is not statistically significant may still be clinically important if it involves a critical pathogen-antimicrobial combination. Conversely, a statistically significant trend based on a large number of isolates may be too small to change clinical practice.

Interpreting Trend Patterns

Several trend patterns warrant specific attention in a surveillance report:

A sustained increase in resistance for a specific pathogen-antimicrobial combination may indicate antimicrobial selection pressure and should trigger stewardship review. A sudden increase may indicate an outbreak of a resistant clone and should trigger infection control investigation. A decrease in resistance may indicate that stewardship interventions are working or that the clonal population has changed.

The keratitis meta-analysis examined regional and temporal trends in antimicrobial susceptibility and found that resistance patterns vary by geographic region [<a href="#ref-6">6</a>]. This finding underscores the importance of local surveillance data instead of relying on national or global estimates.

Stratifying by Specimen Source and Patient Population

Specimen Source as a Stratification Variable

Resistance patterns often differ by specimen source. Isolates from blood, urine, respiratory samples, and wounds may represent different infection types with different resistance profiles. The dermatology surveillance study found that secretion was the most common positive specimen type and that primary infections had higher isolation rates than secondary infections [<a href="#ref-3">3</a>].

Stratifying resistance percentages by specimen source can reveal patterns that are masked in the aggregate. For example, urinary isolates may have higher resistance to certain antimicrobials than bloodstream isolates because of different antimicrobial exposure histories. The surveillance report should include specimen source as a stratification variable when sample sizes permit.

Patient Location and Demographics

Patient location is another important stratification variable. Inpatient isolates often show higher resistance than outpatient isolates because hospitalized patients have more antimicrobial exposure and more healthcare contact. Intensive care unit isolates may show even higher resistance because of the severity of illness and the intensity of antimicrobial use in that setting.

Patient demographics such as age and sex may also be associated with resistance patterns. The dermatology study found that positive cultures were more common in males, patients aged 60 or older, and surgical patients [<a href="#ref-3">3</a>]. These demographic associations may reflect differences in healthcare exposure, underlying conditions, or infection types.

Organism-Specific Considerations

Different organisms require different analytical approaches. Staphylococcus aureus resistance is typically summarized by methicillin resistance status, which is determined by oxacillin or cefoxitin testing. Enterobacterales resistance is often summarized by extended-spectrum beta-lactamase production or carbapenem resistance. Enterococcus resistance is characterized by vancomycin resistance and, more recently, linezolid resistance [<a href="#ref-3">3</a>].

The surveillance report should present organism-specific resistance data in a format that matches clinical decision-making. For Staphylococcus aureus, the methicillin-resistant proportion is the key metric. For Enterobacterales, the proportion susceptible to third-generation cephalosporins and carbapenems is critical. For Pseudomonas aeruginosa and Acinetobacter baumannii, multidrug resistance is the primary concern.

Creating the Report Structure

Executive Summary

The executive summary should state the key findings in plain language for stakeholders who will not read the full report. It should include the most important resistance percentages, any significant trends, and the recommended actions. The summary should be limited to one page and should avoid technical jargon.

The executive summary should answer three questions: What are the current resistance levels for the most important pathogen-antimicrobial combinations? How do these levels compare with previous time periods? What actions are recommended based on these findings?

Methodology Section

The methodology section should document every decision that affects the interpretation of the results. This section should describe the study population, inclusion and exclusion criteria, deduplication method, testing methodology, breakpoint version, and statistical methods. The methodology should be detailed enough that another laboratory could replicate the analysis.

The methodology section should also describe the limitations of the data. Common limitations include small sample sizes for specific pathogen-antimicrobial combinations, changes in testing methodology during the surveillance period, and incomplete clinical data. Acknowledging limitations demonstrates scientific rigor and helps stakeholders interpret the results appropriately.

Results Section

The results section should present the resistance percentages and MIC distributions in tables and figures. The text should highlight the most important findings without repeating every number in the tables. Each table and figure should have a clear title and footnotes explaining any abbreviations or special considerations.

The results should be organized by pathogen group, with subsections for gram-positive organisms, gram-negative organisms, and any organism-specific findings. Within each subsection, the key antimicrobials should be presented in a consistent order to facilitate comparison across time periods.

Discussion and Recommendations

The discussion section should interpret the results in the context of local and national data. It should address whether the observed resistance levels are expected, whether trends are concerning, and what actions are warranted. The discussion should also compare the findings with published surveillance data where appropriate.

The recommendations should be specific and actionable. They should identify which antimicrobials remain appropriate for empirical therapy, which resistance mechanisms require enhanced detection efforts, and which infection control or stewardship interventions should be prioritized. The recommendations should be directed to specific stakeholder groups.

Visualizing Surveillance Data

Tables for Detailed Data Presentation

Tables are the most efficient format for presenting detailed resistance data. A standard format lists the pathogen in the rows and the antimicrobials in the columns, with the percentage of susceptible isolates in each cell. The number of isolates tested should be included either in the cell or in a separate row.

The table should include a footnote indicating the number of isolates tested for each pathogen-antimicrobial combination. Combinations with fewer than a minimum number of isolates should be flagged or excluded. The table should also indicate the breakpoint version used for interpretation.

Figures for Trend Visualization

Line charts are the most effective format for showing temporal trends in resistance percentages. The x-axis should represent time and the y-axis should represent the percentage of resistant or susceptible isolates. Each line should represent a single pathogen-antimicrobial combination, and the chart should include no more than four or five lines to maintain readability.

Bar charts are useful for comparing resistance percentages across specimen sources or patient populations. The bars should be ordered by resistance percentage to make the pattern immediately apparent. Error bars showing confidence intervals should be included when sample sizes are small.

MIC Distribution Charts

MIC distribution charts should show the percentage of isolates at each tested concentration. The x-axis should represent the MIC concentration in doubling dilutions, and the y-axis should represent the percentage of isolates. The clinical breakpoint should be marked with a vertical line so that readers can see the relationship between the distribution and the categorical interpretation.

For temporal comparisons, MIC distributions from different time periods can be overlaid on the same chart using different colors or line styles. This visualization makes shifts in the distribution immediately apparent. A distribution that moves to the right over time indicates decreasing susceptibility even before categorical resistance percentages change.

Quality Control and Data Integrity

Quality Control Organisms and Ranges

Quality control organisms with known MIC ranges must be tested with each batch of clinical isolates. The Clinical and Laboratory Standards Institute publishes expected QC ranges for each antimicrobial-organism combination [<a href="#ref-4">4</a>]. Results outside these ranges indicate that the testing system is not performing correctly and that clinical results from that batch may be unreliable.

The American Type Culture Collection maintains authenticated reference strains that serve as standardized QC organisms [<a href="#ref-5">5</a>]. These strains are characterized to ensure that their MIC values fall within the expected ranges. Laboratories should use authenticated strains instead of laboratory-passaged isolates that may have drifted from the original characteristics.

Tracking QC Performance Over Time

QC results should be tracked over time to detect testing drift. A gradual shift in QC MIC values toward the edge of the acceptable range may indicate a developing problem with the testing system. The Clinical and Laboratory Standards Institute recommends that laboratories monitor QC results using control charts or similar methods [<a href="#ref-4">4</a>].

The surveillance report should include a summary of QC performance for the reporting period. This summary should state the number of QC tests performed, the number of results outside the expected range, and the actions taken in response to out-of-range results. This documentation allows stakeholders to assess the reliability of the surveillance data.

Handling Out-of-Range QC Results

When a QC result falls outside the expected range, the laboratory must investigate the cause before reporting clinical results. Possible causes include contaminated reagents, incorrect incubation conditions, mislabeled QC organisms, or errors in antimicrobial preparation. The investigation should be documented, and the corrective action should be recorded.

Clinical results from a batch with out-of-range QC results should not be included in surveillance analyses unless the investigation demonstrates that the clinical results were unaffected. The surveillance report should document any batches that were excluded for QC reasons.

Common Failure Patterns in Surveillance Reporting

Denominator Errors

The most common error in surveillance reporting is an incorrect denominator. This error occurs when the number of isolates tested for a specific antimicrobial differs from the number of isolates tested for the organism overall. Some antimicrobials may not be tested for all isolates because of testing algorithms or reporting restrictions.

The surveillance report should verify that the denominator for each pathogen-antimicrobial combination matches the number of isolates with a recorded result for that combination. Discrepancies should be investigated and documented.

Breakpoint Version Confusion

Changes in clinical breakpoints can alter resistance percentages without any change in the underlying MIC data. If a laboratory updates its breakpoints but does not document the change, the surveillance report may show an apparent change in resistance that is actually an artifact of the breakpoint change.

The surveillance report should document the breakpoint version used for each time period. When breakpoints change, the report should either reanalyze historical data with the new breakpoints or clearly flag the breakpoint change as a limitation.

Duplicate Isolate Bias

Including duplicate isolates from the same patient inflates the contribution of patients with multiple positive cultures. This bias is particularly problematic for patients with chronic infections who are cultured repeatedly. The surveillance report should apply a deduplication rule and document the rule in the methodology.

Small Sample Size Overinterpretation

Resistance percentages based on small numbers of isolates are unstable and should not be overinterpreted. A single resistant isolate among five tested isolates produces a 20% resistance percentage, but the confidence interval is extremely wide. The surveillance report should flag combinations with small denominators and advise caution in interpretation.

Biosafety and Regulatory Context

Laboratory Biosafety Considerations

Working with clinical bacterial isolates requires appropriate biosafety practices. The Biosafety in Microbiological and Biomedical Laboratories publication from the CDC and NIH provides guidance on risk assessment, containment, and decontamination for work with infectious agents [<a href="#ref-7">7</a>]. Laboratories should follow these guidelines when handling clinical isolates for susceptibility testing and surveillance.

The biosafety level required depends on the organisms being handled. Most routine clinical isolates can be handled at Biosafety Level 2 with appropriate containment practices. Organisms with enhanced transmission or pathogenicity may require additional precautions. The laboratory should conduct a risk assessment for each organism handled.

Professional Standards and Training

The American Society for Microbiology provides professional education and resources for microbiology laboratory practice [<a href="#ref-8">8</a>]. Laboratory professionals should maintain current knowledge of susceptibility testing standards and surveillance methods through continuing education.

The need for standardized training in clinical microbiology has been recognized as a critical issue. A 2021 publication highlighted the need for harmonization of diagnostic procedures and specific guidelines for interpretation and reporting of antimicrobial susceptibility testing results [<a href="#ref-1">1</a>]. Laboratories should ensure that staff are trained in the specific methods used for susceptibility testing and surveillance.

Regulatory and Accreditation Requirements

Laboratories that perform susceptibility testing for clinical purposes may be subject to regulatory and accreditation requirements. These requirements vary by jurisdiction and laboratory type. The surveillance report should be prepared in a manner consistent with applicable requirements.

Whole-genome sequencing is increasingly being used for antimicrobial resistance prediction in some settings. A 2025 publication described the development of a comprehensive pipeline to predict antimicrobial susceptibility from genomic data that was accredited to ISO standards [<a href="#ref-9">9</a>]. This approach may complement or eventually replace phenotypic testing for some organisms, but it requires specialized bioinformatics expertise and validation.

Professional Escalation Criteria

When to Escalate Resistance Findings

Certain resistance findings warrant immediate escalation beyond the routine surveillance report. These include the emergence of resistance to last-line antimicrobials, clusters of resistant organisms suggesting possible transmission, and resistance percentages that exceed established thresholds for action.

The surveillance report should include a section that identifies findings requiring urgent attention. This section should specify which pathogen-antimicrobial combinations are considered critical and what actions should be taken when concerning patterns are detected.

When to Investigate Data Quality Issues

Data quality issues that cannot be resolved through routine data cleaning should be escalated to laboratory leadership. These issues include unexplained shifts in QC results, persistent discrepancies between MIC values and categorical results, and evidence of systematic errors in susceptibility testing.

The escalation should include a description of the problem, the investigation conducted, and the recommended corrective action. The laboratory should document the escalation and the resolution for quality assurance purposes.

When to Seek External Consultation

Some resistance findings may require external consultation with public health authorities or reference laboratories. These include the detection of novel resistance mechanisms, resistance to antimicrobials that are not routinely tested, and outbreaks of resistant organisms that may extend beyond the facility.

The World Health Organization coordinates global antimicrobial resistance surveillance and can provide guidance on reporting and response [<a href="#ref-2">2</a>]. National public health authorities may also provide reference testing and outbreak investigation support.

Decision Framework for Selecting Report Metrics and Analysis Depth

Matching Report Complexity to Stakeholder Needs

A surveillance report fails when it provides either too little detail for technical audiences or too much complexity for decision makers. The solution is a tiered decision framework that matches analysis depth to the specific question being asked. This framework prevents the common failure of producing a single report format that satisfies no audience completely.

The first decision point is identifying the primary consumer of each report section. Clinical staff need categorical susceptibility percentages for empirical therapy guidance. Infection prevention teams need organism-level clustering data and resistance mechanism information. Stewardship committees need temporal trends linked to antimicrobial usage data. Laboratory leadership needs QC performance summaries and methodology documentation. Administrative stakeholders need concise executive summaries with clear action items.

The second decision point is determining the minimum sample size required for each analysis level. A facility processing fewer than 30 isolates per year for a specific pathogen-antimicrobial combination cannot produce meaningful temporal trend analysis. The report should state this limitation explicitly instead of presenting unstable percentages as definitive findings. Published surveillance studies demonstrate that meaningful trend detection requires consistent data collection across multiple years with adequate isolate volumes [<a href="#ref-3">3</a>].

The third decision point is selecting the analytical depth appropriate for the report cycle. Monthly reports should focus on outlier detection and immediate action items. Quarterly reports should include resistance percentage comparisons with the previous quarter and the same quarter in prior years. Annual reports should include full MIC distribution analysis, MIC50 and MIC90 calculations, and statistical trend testing.

Structured Decision Matrix for Report Content

The thresholds in this matrix are operational minimums that laboratories can adjust based on their specific context and stakeholder requirements. The key principle is that the report must state the minimum isolate count used for each analysis level so that readers understand the reliability of each finding.

Selecting Between Susceptibility and Resistance Metrics

The choice between presenting percentage susceptible and percentage resistant depends on the stakeholder audience and the clinical question. Susceptibility percentages are more useful for clinicians selecting empirical therapy because they directly indicate the probability that a given antimicrobial will be effective. Resistance percentages are more useful for stewardship and infection control audiences because they highlight the magnitude of the resistance problem.

The report should present both metrics when possible, with susceptibility percentages in the clinical guidance tables and resistance percentages in the trend analysis figures. When sample sizes are limited, the report should prioritize the metric most relevant to the primary stakeholder for that section.

Determining When MIC Distribution Analysis Is Warranted

MIC distribution analysis adds value when categorical resistance percentages are stable but clinical outcomes are deteriorating, when a new resistance mechanism is suspected in the local population, or when breakpoint changes are being considered. The dermatology surveillance study demonstrated that tracking MIC distributions alongside categorical results provides earlier detection of emerging resistance patterns than categorical results alone [<a href="#ref-3">3</a>].

The decision to include MIC distribution analysis should be documented in the report methodology. Laboratories with limited resources can restrict MIC distribution analysis to critical pathogen-antimicrobial combinations, such as carbapenems for Enterobacterales or vancomycin for Enterococcus species, instead of analyzing every combination.

Implementing the Framework in Practice

The framework requires a documented decision process that is applied consistently across reporting cycles. The laboratory should maintain a written protocol that specifies which analyses are performed at each reporting level, the minimum isolate counts required for each analysis, and the stakeholders who receive each report section.

The protocol should also specify the escalation pathway when minimum isolate counts are not met. Options include combining data from adjacent time periods, reporting the data with explicit confidence interval warnings, or excluding the combination from the report with a note explaining the exclusion. The chosen option should be documented in each report so that stakeholders understand why certain data are absent.

Common Failure Patterns in Metric Selection

The most common failure is presenting resistance percentages without confidence intervals when denominators are small. A report that states 40% resistance based on 5 isolates without acknowledging the wide confidence interval misleads stakeholders into overinterpreting unstable data.

Another common failure is changing the metric between reporting periods without documentation. A report that switches from percentage susceptible to percentage resistant without explanation makes temporal comparison impossible. The methodology section must document the metric used in each reporting period.

A third failure is applying the same analysis depth to all pathogen-antimicrobial combinations regardless of clinical importance. A report that gives equal analytical weight to a rarely used antimicrobial and a last-line therapeutic agent fails to prioritize stakeholder attention appropriately. The report should flag critical combinations for enhanced analysis and interpretation.

Recording Framework Decisions

Each report should include a decision log that documents the analytical choices made for that reporting period. The log should record the minimum isolate thresholds used, the metric selected for each section, the analysis depth applied to each pathogen-antimicrobial combination, and any deviations from the standard protocol.

The decision log serves multiple purposes. It provides transparency for stakeholders who need to understand the basis for reported findings. It supports continuity when laboratory staff change. It creates an audit trail for accreditation and quality assurance reviews. The log should be maintained as part of the laboratory quality management system.

Professional Escalation Criteria for Framework Deviations

When the decision framework cannot be applied because of data limitations or unusual findings, the laboratory should escalate to the appropriate authority. Situations requiring escalation include persistent inability to meet minimum isolate counts for critical combinations, unexpected shifts in MIC distributions that suggest testing problems, and stakeholder requests for analyses that exceed the validated framework.

The escalation should document the specific deviation, the reason for the deviation, and the proposed resolution. The laboratory leadership should review the escalation and determine whether the framework requires revision or whether the deviation is a one-time event that can be documented in the report methodology.

Validation of the Framework

The decision framework should be validated against historical data before implementation. The laboratory should apply the framework to at least two years of retrospective data to confirm that the minimum isolate thresholds produce stable estimates and that the analysis depth is appropriate for the available data volumes.

Validation should also include stakeholder feedback. The laboratory should ask report recipients whether the analysis depth meets their needs and whether the metric selection supports their decision-making. This feedback should be incorporated into framework revisions on an annual basis.

The framework should be reviewed whenever testing methodologies change, breakpoints are updated, or new resistance mechanisms emerge in the local population. The review should assess whether the minimum isolate thresholds remain appropriate and whether the analysis depth requires adjustment.

Frequently Asked Questions

What is the difference between MIC data and categorical susceptibility results?

MIC data are quantitative measurements of the lowest antimicrobial concentration that inhibits visible bacterial growth, expressed in µg/mL. Categorical results are qualitative classifications of susceptible, intermediate, or resistant that are derived by comparing the MIC to clinical breakpoints. MIC data provide more information than categorical results because they show how close an isolate is to the breakpoint threshold.

How many isolates are needed to calculate a reliable resistance percentage?

There is no universal minimum number, but resistance percentages based on fewer than 10 isolates are generally considered unstable. The confidence interval around a resistance percentage narrows as the number of isolates increases. The surveillance report should flag pathogen-antimicrobial combinations with small denominators and advise caution in interpretation.

How should duplicate isolates from the same patient be handled?

The standard approach is to include only the first isolate per patient per defined time period, typically 30 days, for each organism species. This approach prevents patients with multiple positive cultures from being overcounted in the analysis. The deduplication method should be documented in the report methodology.

What is the MIC50 and MIC90 and why are they useful?

The MIC50 and MIC90 are the MIC values that inhibit 50% and 90% of the tested isolates, respectively. They provide a compact description of the MIC distribution. The MIC50 represents the typical susceptibility of the population, while the MIC90 describes the more resistant end of the distribution.

How should intermediate results be handled in resistance calculations?

Intermediate results can be combined with resistant results into a nonsusceptible category or treated as a separate category. The approach should be documented in the report methodology. Combining intermediate with resistant results provides a conservative estimate of antimicrobial effectiveness.

What quality control data should be included in a surveillance report?

The report should include a summary of QC performance for the reporting period, including the number of QC tests performed, the number of results outside the expected range, and the actions taken in response to out-of-range results. This documentation allows stakeholders to assess the reliability of the surveillance data.

How often should surveillance reports be generated?

The frequency depends on the volume of isolates and the needs of stakeholders. Annual reports are common for summarizing long-term trends. Quarterly reports provide more timely detection of emerging resistance patterns. Monthly reports may be appropriate for facilities with high isolate volumes or active outbreak investigations.

What should be done when a concerning resistance trend is detected?

A concerning trend should be escalated to the appropriate stakeholders, including the antimicrobial stewardship committee, infection prevention team, and laboratory leadership. The escalation should include a description of the finding, the data supporting it, and recommended actions. Public health authorities should be notified when the finding suggests a broader public health threat.

Related Bacteriology Guides

• Salmonellosis in Poultry: Serovar Surveillance, Antimicrobial Resistance, and Egg Safety
• Salmonella in the Poultry Industry: Report on Prevalence, Control, and Public Health Impact
• Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus: Genomic Epidemiology and One Health Implications
• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Salmonellosis in Poultry: Public Health and Flock Management

References and Further Reading

References

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.